Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice (Q44738351)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Judith Del Campo

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Madelene Lindqvist

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Maribel Cuello

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Malin Bäckström

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Osmir Cabrerra

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Josefine Persson

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Oliver Perez

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Ali M Harandi

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

language of work or name

0 references

publication date

27 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1193-1200

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Protective immunity against HSV-2 in the mouse vagina

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Recent progress in herpes simplex virus immunobiology and vaccine research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Herpes simplex virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Nanoparticles and microparticles as vaccine-delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

New vaccines require potent adjuvants like AFPL1 and AFCo1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

TLR signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

B cell intrinsic MyD88 signals drive IFN-gamma production from T cells and control switching to IgG2c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.035

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.11.035

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44738351&oldid=2035636284"